Uncategorized

OliX Pharmaceuticals Presents Preclinical Data Showing Synergistic Weight Loss from anti-NASH siRNA and Semaglutide Combination Treatment

OliX Pharmaceuticals, Inc. today announced that the Company presented its latest study data from preclinical studies identifying synergistic effects in weight loss when using its non-alcoholic steatohepatitis (NASH) treatment candidate OLX702A in combination with semaglutide.

OliX Pharmaceuticals Presents Preclinical Data Showing Synergistic Weight Loss from anti-NASH siRNA and Semaglutide Combination Treatment Read More »

Fusion Pharmaceuticals Announces First Quarter 2023 Financial Results and Clinical Program Updates

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced financial results for the first quarter ended March 31, 2023 and provided an update on clinical and corporate developments.

Fusion Pharmaceuticals Announces First Quarter 2023 Financial Results and Clinical Program Updates Read More »

Scroll to Top